Treatment for chronic hepatitis B (CHB) disease is
|
|
- Brook Fletcher
- 5 years ago
- Views:
Transcription
1 Antiviral Activity and Safety of LB80380 in Hepatitis B e Antigen Positive Chronic Hepatitis B Patients with Lamivudine-Resistant Disease Man-Fung Yuen, 1 * Kwang-Hyub Han, 2 * Soon-Ho Um, 3 Seung Kew Yoon, 4 Hye-Ryon Kim, 5 John Kim, 5 Chung Ryeol Kim, 5 and Ching-Lung Lai 1 We aimed to determine the antiviral activity and safety of a new nucleotide analogue, LB80380, in chronic hepatitis B (CHB) patients with lamivudine-resistant virus. Sixty-five patients with lamivudine-resistant virus were randomized to receive five ascending daily doses (30, 60, 90, 150, 240 mg) of LB LB80380 was given together with lamivudine for the first 4 weeks, followed by 8 weeks of LB80380 monotherapy. This was then followed by 24 weeks of adefovir. Hepatitis B virus (HBV) DNA levels, serology, liver biochemistry, and safety were monitored. The extent of the HBV DNA reduction at week 12 was dose-dependent. The mean reduction from baseline was 2.81, 3.21, 3.92, 4.16, and 4.00 log 10 copies/ml for the five ascending dose groups. The dose-proportionate effect was statistically significant (P < 0.001) with a decrease of HBV DNA levels by an average of 1.54 log 10 copies/ml for every 1-unit increase in log 10 dose of LB In 93.4% of patients, HBV DNA decreased by >2 log 10 copies/ml, and 11.5% of patients had undetectable HBV DNA levels (<300 copies/ml) by week 12. HBV DNA suppression was maintained during the 24 weeks of adefovir treatment. Hepatitis B e antigen seroconversion and normalization of alanine aminotransferase were seen in 14.6% and 24.6% of patients, respectively, at week 12; 44.6% of patients experienced mild and self-limiting adverse events, none of which were attributed to the study drug. Conclusion: LB80380 at doses of up to 240 mg is safe, well tolerated, and effective at reducing viral load in CHB patients with lamivudine-resistant virus for a period of 12 weeks. (HEPATOLOGY 2010;51: ) Treatment for chronic hepatitis B (CHB) disease is rapidly evolving after the introduction of nucleoside/nucleotide analogs (NAs). The first nucleoside analog lamivudine (L-nucleoside) was licenced in 1998, 1 and four more NAs were approved subsequently: adefovir in 2002, entecavir in 2005, telbivudine in 2006, and, most recently, tenofovir in Apart from having a wider option of drug treat- Abbreviations: AE, adverse event; ALT, alanine aminotransferase; CHB, chronic hepatitis B; CI, confidence interval; CrCl, creatinine clearance; DLT, dose-limiting toxicity; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, nucleoside/nucleotide analog; PP, per-protocol; SD, standard deviation; ULN, upper limit of normal. From the 1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong; the 2 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; the 3 Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea; the 4 Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea; and 5 LG Life Sciences, Seoul, Korea. Received June 15, 2009; accepted October 24, This study has been sponsored by LG Life Sciences; research grants were given to the investigators. This study was also supported by grants from Anadys Pharmaceuticals, Inc. and Korean Ministry for Health, Welfare and Family Affairs. This study has been registered (registration number NCT ) in ClinicalTrials.gov (URL LB80380&rank 1). This study was supported by LG Life Sciences which also provided the drug LB The data collection and data report were carried out by an independent data management company, Covance Pty Limited, Australia. The analysis and the writing of the manuscript were mainly performed by the first two authors as well as the corresponding author. The drug company employees read and commented on the manuscript, and gave their approval. *These authors contributed equally to this work. Address reprint requests to: Professor Ching-Lung Lai, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road, Hong Kong. hrmelcl@hkucc.hku.hk; fax: (852) Copyright 2009 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflicts of interest: M. F. Y. and C. L. L. have received speakers honoraria from LG Life Sciences. H. R. K. and C. R. K. are full-time employees of LG Life Sciences. J. K. is a former employee of LG Life Sciences. 767
2 768 YUEN, HAN, ET AL. HEPATOLOGY, March 2010 ment, the treatment strategy has also been conceptually changed, aiming at prolonged viral suppression to achieve reduction in the rate of development of cirrhosis and hepatocellular carcinoma. 3 The main limitation of using NAs is the emergence of drug resistance. Because lamivudine was the first available NA, it has been used extensively worldwide. It has been shown that the chance of lamivudine resistance is approximately 76% after 5 years of treatment. 4 Adefovir resistance also occurs in 20%-29% of treatment-naïve patients after 5 years of therapy. Although adefovir is effective in suppressing lamivudine-resistant hepatitis B virus (HBV), its potency is only modest at the licensed dosage. Adefovir treatment for 48 weeks for patients with lamivudine-resistant HBV is associated with a 4-log HBV DNA level reduction and 53% chance of normalization of alanine aminotransferase (ALT) levels. 5 Lamivudine-resistant HBV is partially refractory to entecavir treatment requiring increased doses of entecavir. In addition, entecavir resistance occurs in 51% of patients with lamivudine-resistant HBV after 5 years of treatment. 6 Tenofovir is highly effective for treatment-naïve patients. 7 Tenofovir is also effective in patients with lamivudine-resistant virus, although more long-term data on the development of tenofovir resistance is still not available. It has been shown in in vitro studies and case reports that different NAs are effective for drug-resistant HBV to other NAs. For instance, tenofovir is effective against adefovir-resistant strains 8 and adefovir is effective against entecavir resistant strains. 9 There is therefore a need to develop newer NAs to provide complementary and possibly better viral suppression for both treatment-naïve patients and patients with drug-resistant HBV. LB80380 is a new acyclic nucleotide phosphonate with chemical similarity to adefovir and tenofovir. It is the prodrug of LB80331, which in turn will be metabolized to LB80317, the active metabolite with antiviral effect for HBV after further intracellular phosphorylation to the triphosphate form. 10 Experiments conducted in Huh7 cells show that there is no reduction in mitochondrial DNA and no lactic acid accumulation with LB According to a phase Ib dose escalation study in treatment-naïve patients, 4-week treatment of LB80380 is associated with a 3- to 4.2-log reduction of HBV DNA and the dose ranged from 30 to 240 mg daily. 12 In an in vitro experiment, this drug has also been shown to be effective against HBV mutants resistant to lamivudine, adefovir, entecavir, and telbivudine. 13 We report the results of an open-label, multicenter dose escalation study to assess the antiviral activity and safety of LB80380 for 12 weeks in CHB patients with lamivudine-resistant disease. Patients and Methods Study Design and Sample Size. This study was a phase II, open-label, multicenter, dose escalation study to evaluate the antiviral activity and safety of LB80380 during a 12-week treatment period. This study was conducted at four centers in Hong Kong and Korea. Because the efficacy assessment was descriptive, the sample size calculation was based on the accuracy of the confidence interval (CI) for the primary efficacy parameter (mean reduction in HBV DNA at 12 weeks on the log 10 scale). The accuracy was measured by the width of the 95% CI. The two-sided 95% CI for the mean was estimated with the assumption that the distribution of the reduction on the log scale is symmetric and normally distributed. Assuming a potential dropout rate of at most 25% over the treatment period of 12 weeks, a minimum of twelve patients were to be enrolled into each dose group to ensure that at least nine would be evaluable. The treatment period was divided into two parts: an initial 4-week treatment period (part 1) during which dose escalation was assessed, followed by an 8-week extension period (part 2). The treatment period was followed by a 24-week follow-up period. During the initial 4 weeks of the treatment period (part 1), patients received LB80380 together with lamivudine 100 mg once daily. The overlapping 4-week period of LB80380 and lamivudine was designed to minimize the risk of hepatitis flares that might occur if the therapy was switched directly to LB80380 monotherapy. Five doses of LB80380 were planned: 30 mg (group 1); 60 mg (group 2); 90 mg (group 3); 150 mg (group 4), and 240 mg (group 5). After completion of 4-week dosing at each level of LB80380 combined with lamivudine 100 mg in part 1, patients were given only LB80380 at the same dose for an additional 8 weeks in part 2, unless more than two patients in the group experienced dose-limiting toxicity (DLT) during part 1. DLT was defined as the occurrence of one of the following: grade 4 ALT ( 10 baseline) with evidence of hepatic decompensation; prothrombin time 3 seconds prolonged relative to the normal control; serum albumin level 30 g/l; total bilirubin level 5 upper limit of normal (ULN); serum creatinine 6 ULN or amylase value 5 ULN; any other grade 4 clinical or laboratory toxicity considered to be reasonably or possibly related to the study drug; or any clinical and laboratory adverse events of any intensity considered to be reasonably or possibly related to study drug
3 HEPATOLOGY, Vol. 51, No. 3, 2010 YUEN, HAN, ET AL. 769 and necessitating permanent discontinuation of study drug. The laboratory measures performed at every study visit for safety monitoring included complete blood count, liver and renal function (urea and creatinine), serum levels of amylase (lipase if serum amylase 1.5 ULN), lactic acid, and creatine kinase. Estimated creatinine clearance (CrCl) according to the Cockroft-Gault formulation (based on serum creatinine level, age, body mass, and sex) were calculated in all the study visits. After the 12-week treatment period, all patients were given adefovir dipivoxil 10 mg/day for 24 weeks (follow-up period). This treatment protocol was applied in groups 2-5. (Group 1 and one patient in group 2 were recruited under an earlier protocol in which part 2 consisted of 20 weeks instead of 8 weeks of treatment with LB80380 monotherapy. Due to a change of protocol when part 2 was in progress, these patients received 9-16 weeks of treatment with LB80380 alone instead of the 20 weeks originally planned.) Patients visited the study sites for assessment of safety and antiviral activity at weeks 1, 2, 3, and 4 during part 1 and at weeks 8 and 12 during part 2. Thereafter, patients attended six follow-up visits at weeks 16, 20, 24, 28, 32, and 36. All available safety and tolerability data were reviewed before dose escalation. All patients within each group had to complete part 1 of the treatment period before enrollment at the next planned dose could begin. Dose escalation to the subsequent group could only be initiated if fewer than three patients experienced DLT within a given dose level during part 1 of the treatment period. Furthermore, if more than two cumulative patients within a group experienced DLT over the entire treatment period including part 1 and part 2, then further dose escalation would not be initiated. The study was approved by the institutional review boards in all the study centers in Hong Kong and Korea. It was conducted in accordance with the study protocol and in compliance with current International Conference on Harmonisation/Good Clinical Practice guidelines, the ethical principles stated in the 1964 Declaration of Helsinki and subsequent revisions (including the 2000 Edinburgh Revision), and other applicable international and regional regulatory requirements. Informed written consent was obtained from all the patients. Inclusion and Exclusion Criteria. The present study recruited patients with the following criteria: age years; presence of serum HBV surface antigen (HBsAg) for at least 6 months; and presence of hepatitis B e antigen (HBeAg) for more than 1 month with compensated liver disease. All patients had lamivudine resistance due to YMDD mutant HBV with documented detection of the HBV mutants rtm204v or rtm204i with or without the upstream mutant of rtl180m by line probe assay (INNO-LiPA HBV DR1; Innogenetics, Ghent, Belgium). All had received continuous lamivudine treatment for 6 months or more. Other inclusion criteria were: HBV DNA levels copies/ml (measured by the CO- BAS Amplicor HBV Monitor assay; Roche Diagnostics, Branchburg, NJ; lower limit of detection 300 copies/ml); ALT value between 1.5 and 10 ULN; and for women of child-bearing potential, negative serum pregnancy test prior to study entry, and willingness to use at least two contraception methods including a barrier method. Patients with the following criteria were excluded: coinfection with hepatitis C, hepatitis D, and human immunodeficiency virus; pregnancy or breast-feeding; use of known nephrotoxic or hepatotoxic agents; treatment with immunomodulatory agents or corticosteroids within 6 months prior to study entry; decompensated liver disease with clinical complications of cirrhosis; prothrombin time 3 seconds prolonged relative to the normal control; serum albumin 30 g/l and bilirubin 2.5 ULN; or other laboratory parameters, including hemoglobin 9.0 g/dl (unless due to haemoglobinopathy), absolute neutrophil count /L, platelet count /L, creatinine 133 mol/l, serum amylase 1.5 ULN, lipase 1.5 ULN, alpha-fetoprotein level 20 ng/ml, and ultrasonography performed prior to baseline with findings indicative of hepatocellular carcinoma. Efficacy and Safety Evaluations. The efficacy variable was serum HBV DNA levels. The primary efficacy endpoint was a reduction in log 10 serum HBV DNA level from baseline at week 12. Secondary efficacy endpoints included: reduction in log 10 serum HBV DNA level from baseline at week 4; proportion of patients with HBeAg seroconversion at week 12; proportion of patients with HBsAg seroconversion at week 12; and proportion of patients with ALT normalization at week 12. Evaluation of safety of the study drug was based on adverse event (AE) and serious AE data, DLT data, clinical laboratory reports, physical examinations, and vital signs. The predetermined amount of creatinine increase was set as 125% of the baseline creatinine level, and this was for easy alertness of possible abnormal data to the investigators. HBeAg seroconversion was defined as loss of HBeAg with the development of antibody to HBeAg. Virologic rebound was defined as an increase of HBV DNA level by more than 1 log compared with the nadir in patients who achieved more than 1 log reduction of HBV DNA during the treatment period compared with baseline HBV DNA levels.
4 770 YUEN, HAN, ET AL. HEPATOLOGY, March 2010 Fig. 1. Patients deposition of the study. *Excluded from PP population because of identification of violation of inclusion criteria after completion of the study (HBeAg positivity 1 month prior to screening). ITT, intention-to-treat population; PP, per-protocol population; WD, patients who withdrew from study. Surveillance of possible LB80380 and adefovir viral mutations were not conducted because of the limited duration of LB80380 treatment of 12 weeks and adefovir treatment for 24 weeks. Populations for Analysis. Evaluation of patient disposition was based on the enrolled population. The perprotocol (PP) population included all patients who were treated for at least 12 weeks with LB80380 with at least 80% compliance and had no major protocol violations. The intention-to-treat population included all patients who received at least one dose of the study medication and had serum HBV DNA values at baseline and for at least one other visit during the 12-week treatment period. Demographic and subsequent analyses were based on the PP population. Drug safety was monitored in all patients who received at least one dose of study medication. Patient distribution and the components of the populations of analysis are illustrated in Fig. 1. One patient from group 2 was not included in the intention-to-treat population because this patient was withdrawn from the study on day 6 (due to a screening ALT 400 U/L) and consequently there were no postbaseline data for the analysis of efficacy for this patient. Four patients were excluded from the PP population due to protocol deviations. These include the group 2 patient mentioned above, one group 3 patient due to a low baseline platelet count, and one group 4 patient due to a low baseline ALT level. These three patients therefore did not complete 12 weeks of treatment as required to warrant inclusion in the PP population. The fourth patient from group 5 did not fulfill the inclusion criterion that patients had to be HBeAg-positive for more than 1 month prior to the screening visit. Statistical Analysis. Baseline parameters of the five groups were compared using the Kruskal-Wallis test. The decrease in log 10 serum HBV DNA level from baseline to week 4 and 12 was calculated as baseline log 10 serum value minus week 4 and 12 log 10 serum value. A positive change from baseline corresponded to a reduction in the log 10 serum HBV DNA level and was indicative of an improvement. A linear regression model was used to assess dose response in the efficacy endpoint in the PP population. The regression analysis was performed using PROC REG using log 10 dose as the covariate. The regression coefficient, or dose proportionality constant, was reported together with a 95% CI. For each model, the null hypothesis of dose independence was tested against the two-sided alternative using a Wald test, and a P value generated. Because these analyses are considered exploratory, no adjustment for multiple comparisons was made. The Cochran-Armitage test for trend was used to test for trend in the proportion of patients with HBeAg seroconversion, HBsAg seroconversion, and ALT normalization at week 12 across the five dose groups (30, 60, 90, 150, or 240 mg/day). The test for trend was performed using PROC FREQ with the TREND option. The changes of the mean CrCl at baseline and week 12 were compared by way of paired t test. An exact, two-sided test was conducted at the 5% significance level. Results Baseline Characteristics. The baseline demographics, liver biochemistry, HBV DNA levels, and pattern of lamivudine resistance for the PP population are presented in Table 1. Effect of LB80380 on Serum HBV DNA. At week 12, there was a decrease from baseline in serum HBV DNA levels in all dose groups in the PP population (Table 2). The mean serum HBV DNA at week 12 for the five dose groups was: group log 10 copies/ml (standard deviation [SD] 1.34); group log 10 copies/ml (SD 1.24); group log 10 copies/ml (SD 1.14); group log 10 copies/ml (SD 1.33); and group log 10 copies/ml (SD 0.99). The extent of the reduction in viral load from baseline to week 12 was dose-dependent up to the 150 mg daily dose (Table 2). The mean reduction from baseline viral load was as follows: group log 10 copies/ml (95% CI ); group log 10 copies/ml (95% CI ); group log 10 copies/ml (95% CI ); group log 10 copies/ml (95% CI ); and group log 10 copies/ml (95% CI ). The reduction of HBV DNA levels of the five groups of the PP population over the whole study period are illustrated in Fig. 2. In all dose groups in the PP popula-
5 HEPATOLOGY, Vol. 51, No. 3, 2010 YUEN, HAN, ET AL. 771 Table 1. Baseline Demographics, Liver Biochemistry, HBV DNA Levels and Pattern of Lamivudine Resistance for the PP Population Group 1, 30 mg/day Group 2, 60 mg/day Group 3, 90 mg/day Group 4, 150 mg/day (n 11) Group 5, 240 mg/day (n 11) Age, years Mean (SD) 38.0 (12.1) 35.6 (9.8) 38.8 (10.8) 46.9 (9.6) 45.3 (12.2) Median (range) 40 (21 60) 39 (23 50) 42 (24 55) 47 (30 62) 45 (26 64) Sex (M:F) 11:2 12:1 13:0 8:3 10:1 Albumin,* g/l 43 (35 52) 41 (38 48) 46 (37 49) 43 (40 47) 45 (39 50) Bilirubin,* mol/l 15.4 ( ) 14.5 (7 30.3) 12 ( ) 10.3 (8 26.5) 13.9 ( ) ALT,* U/L 87 (50 321) 141 (84 463) 88 (48 258) 161 (77 405) 71 (53 181) HBV DNA levels, copies/ml Mean (SD) 8.3 (0.62) 7.8 (0.82) 7.8 (1.27) 8.0 (0.70) 8.2 (0.87) Median (range) 8.5 ( ) 8.1 ( ) 8.3 ( ) 8.1 ( ) 8.4 ( ) Mean duration of lamivudine treatment, months (SD) 47.7 (15.9) 45.5 (29.3) 37.6 (22.0) 56.2 (32.7) 36.5 (25.4) Lamivudine resistance pattern L180M (%) 13 (100) 10 (76.9) 13 (100) 10 (90.9) 11 (100) M204I (%) 10 (76.9) 9 (69.2) 6 (46.2) 7 (63.6) 9 (81.8) M204V (%) 9 (69.2) 7 (53.8) 8 (61.5) 8 (72.7) 8 (72.7) There were no significant differences in the demographics, liver biochemistry, and HBV DNA levels between the five groups (P 0.05). *Values are expressed as the median (range). tion, mean HBV DNA copy number decreased incrementally from baseline to week 12. In group 1, patients achieved a peak reduction in mean HBV DNA at week 24, after which mean HBV DNA levels remained relatively constant. In group 2, patients achieved a peak reduction at around week 16, after which mean HBV DNA decreased slightly. In group 3, the reduction in mean HBV DNA was most significant between baseline and week 12, yet HBV DNA copy number continued to decrease slightly up to week 36. In group 4, patients achieved a peak reduction in mean HBV DNA at week 12, after which time it remained relatively constant. In group 5, patients achieved a peak reduction in mean HBV DNA at week 12, the mean HBV DNA copy number increasing thereafter from the week 12 level between weeks 16 and 36. Increasing doses of LB80380 produced greater mean reductions in HBV DNA levels as illustrated in Fig. 3. Table 2. Reduction in Serum HBV DNA in the PP Population HBV DNA (log 10 ) Group 1, 30 mg/day Group 2, 60 mg/day Group 3, 90 mg/day Group 4, 150 mg/day (n 11) Group 5, 240 mg/day (n 11) Baseline Mean (SD) 8.31 (0.62) 7.82 (0.82) 7.78 (1.27) 8.00 (0.70) 8.19 (0.87) Median (range) 8.54 ( ) 8.08 ( ) 8.26 ( ) 8.05 ( ) 8.39 ( ) Week 4 Mean (SD) 6.22 (1.11) 5.30 (0.92) 5.12 (1.32) 5.18 (1.13) 5.58 (1.10) Median 6.67 ( ) 5.37 ( ) 5.29 ( ) 5.27 ( ) 5.82 ( ) Change at week 4* Mean (SD) 2.09 (0.68) 2.52 (0.69) 2.66 (0.72) 2.82 (0.74) 2.62 (0.62) 95% CI of mean Median (range) 2.02 ( ) 2.66 ( ) 2.49 ( ) 3.10 ( ) 2.50 ( ) 2 log 10 decrease, n (%) 7 (53.8) 10 (76.9) 11 (84.6) 9 (81.8) 10 (90.9) 300 copies/ml, n (%) 0 (0) 0 (0) 1 (7.7) 0 (0) 0 (0) Week 12 Mean (SD) 5.50 (1.34) 4.60 (1.24) 3.86 (1.14) 3.84 (1.33) 4.19 (0.99) Median (range) 5.75 ( ) 4.49 ( ) 4.12 ( ) 3.71 ( ) 4.41 ( ) Change at week 12* Mean (SD) 2.81 (1.06) 3.21 (1.18) 3.92 (0.94) 4.16 (0.97) 4.00 (0.32) 95% CI of mean Median (range) 2.75 ( ) 3.49 ( ) 3.95 ( ) 4.17 ( ) 3.96 ( ) 2 log 10 decrease, n (%) 10 (76.9) 12 (92.3) 13 (100) 11 (100) 11 (100) 300 copies/ml, n (%) 1 (7.7) 0 (0) 2 (15.4) 3 (27.3) 1 (9.1) *A positive decrease indicates an improvement from baseline.
6 772 YUEN, HAN, ET AL. HEPATOLOGY, March 2010 Fig. 2. Mean change in serum HBV DNA load over time in PP population. B, baseline; Lam, lamivudine; S, screening. Fig. 3. Mean decrease from baseline to week 12 (upper line) and from baseline to week 4 (lower line) in log 10 serum HBV DNA and the least-squares regression lines in the PP population.
7 HEPATOLOGY, Vol. 51, No. 3, 2010 YUEN, HAN, ET AL. 773 The dose proportionality constant was 1.54 (95% CI ). As such, HBV DNA levels would have a decrease by an average of 1.54 log 10 copies/ml for every 1 unit increase in log 10 dose of LB The dose-proportionate effect of LB80380 on HBV DNA was statistically significant (P 0.001). All except four patients (57/61 [93.4%]) had a decrease from baseline to week 12 in serum HBV DNA copy number of 2 log 10 units or more. At week 12, 11.5% of the PP population (7/61) had undetectable HBV DNA levels (1 in group 1; 2 in group 3; 3 in group 4; 1 in group 5). The HBV DNA levels and reduction of HBV DNA levels from baseline at week 4 are also described in Table 2. The dose proportionality constant was 0.65, with 95% CI (Fig. 3). HBV DNA levels would have a decrease by an average of 0.65 log 10 copies/ml for every 1 unit increase in log 10 dose of LB The dose-proportionate effect of LB80380 on HBV DNA was statistically significant (P 0.025). In all except group 5, the highest-dose group, the antiviral effect of 12 weeks of treatment with LB80380 was maintained during the 24-week follow-up period while the patients were maintained on adefovir. In groups 1, 2, and 3, there was a slight reduction in mean HBV DNA level between week 12 and week 24: group log 10 copies/ml (SD 1.08); group log 10 copies/ml (SD 0.82); and group log 10 copies/ml (SD 0.40). In groups 4 and 5 there was a slight increase in mean HBV DNA level: group log 10 copies/ml (SD 0.55) and group (SD 0.85). Thirteen patients experienced a virologic rebound during the whole study period. All the episodes of rebound occurred after switching to adefovir. Of these 13 patients, six (one from group 3, five from group 5) had virologic rebound 4 weeks after switching from LB80380 to adefovir. The remaining seven patients (three from group 2, one from each of the other groups) had the virologic rebounds at variable time points during the 24 weeks of adefovir treatment. HBeAg Seroconversion and Loss of HBsAg. Excluding patients from group 1 in whom serology testing was not conducted at week 12 before protocol amendment, seven patients in the PP population (7/48 [14.6%]) achieved HBeAg seroconversion at week 12 (one in group 2, three in group 3, two in group 4, and one in group 5). No dose-dependent effect of LB80380 on HBeAg seroconversion was observed (P 0.85). None of the study patients lost HBsAg at week 12. ALT Normalization. At week 12, 24.6% (15/61) of patients in the PP population showed normalization of ALT (three in group 1, one in group 2, five in group 3, five in group 4, one in group 5). No dose-dependent effect of LB80380 on ALT normalization was observed (P 0.90). Adverse Events. Twenty-nine out of 65 (44.6%) patients experienced a total of 65 adverse events during the period of observation. Most of these events appeared to occur in group 1, where 69.2% (9/13) of the patients experienced at least one AE. None of the 65 events were considered to be related to study medication. The most frequently occurring AEs are listed in Table 3. There were no serious or life-threatening (grade 4) AEs. There were no withdrawals due to an AE. The majority (56/65 [86.2%]) of the AEs were of mild (grade 1) intensity. There were two AEs of severe (grade 3) intensity. Eighteen patients had increases in ALT levels during the entire study period (four in group 1, three in group 2, three in group 3, five in group 4, and three in group 5). One group 3 patient exhibited hepatic flare following the end of treatment with lamivudine, with ALT levels increasing from 298 U/L (5.6 ULN) at week 4 to 584 U/L (11.0 ULN) at week 8. This patient already had very high ALT values of 263 U/L at screening and 258 U/L at baseline. This patient s ALT level decreased to 73 IU/L at week 12 and normalized by the end of the study. Mean change in estimated CrCl from baseline was variable, within dose groups as well as between dose groups at week 12 (end of LB80380 treatment). The mean changes of CrCl from baseline to week 12 for groups 1 to 5 were 5.67 (SD 9.58), 0.52 (SD 9.14), 1.75 (SD 12.0), 4.87 (SD 10.65), and 1.99 (SD 12.26) ml/minute, respectively. The mean CrCl at baseline and week 12 were ml/minute (SD 24.96) and ml/minute (SD 22.14) for group 1; ml/minute (SD 13.05) and ml/minute (SD 14.44) for group 2; ml/ minute (SD 29.33) and ml/minute (SD 25.86) for group 3; ml/minute (SD 20.27) and ml/minute (SD 24.79) for group 4; and ml/ minute (SD 21.23) and ml/minute (29.67) for group 5, respectively. There were no significant differences in the CrCl between the values at baseline and week 12 in all the five groups (P 0.05). The exact CrCl values at baseline, week 12 (end of LB80380 treatment), and week 36 (end of adefovir treatment) for all individual patients in the five groups are depicted in Fig. 4. Two patients in group 1 experienced an increase in creatinine greater than the predetermined amount at week 28 and week 36, respectively. The CrCl were 78.6 ml/minute and ml/minute, respectively. Discussion According to our previous study of LB80380 given for 4 weeks in treatment-naïve CHB patients, there is a dose-
8 774 YUEN, HAN, ET AL. HEPATOLOGY, March 2010 Table 3. AEs Observed in the Study Population Adverse Event* Group 1, System Organ Class Symptom 30 mg/day Group 2, 60 mg/day (n 14) Group 3, 90 mg/day (n 14) Group 4, 150 mg/day (n 12) Group 5, 240 mg/day (n 12) Overall Incidence, n (%) Gastrointestinal disorders Respiratory, thoracic, and mediastinal disorders Nervous system disorders Infections and infestations General disorders and administration site conditions Musculoskeletal and connective tissue disorders Abdominal (3.08) discomfort Upper abdominal (3.08) pain Dyspepsia (3.08) Cough (10.77) Rhinorrhoea (3.08) Headache (9.23) Influenza (6.15) Fatigue (3.08) Myalgia (3.08) *AEs experienced by more than one patient ( 1) in the safety population are presented in order of the system organ class with the highest number of AEs for the total safety population. proportional effect on HBV DNA reduction with an increasing dose. 12 The maximal HBV DNA suppression with 4 logs HBV DNA reduction after 4 weeks is achieved with the dose of equal or higher than 60 mg daily. In the current study, for lamivudine-resistant disease, a doseproportional effect was also demonstrated with increasing doses of LB80380 up to 150 mg daily. This could be mathematically expressed by the dose-proportional constants for every single log unit increase in the dose for week 4 and 12 (Fig. 3). The maximal mean HBV DNA reduction was achieved at the dose of 150 mg daily (group 4) (Table 2, Fig. 2), with 4.16 logs copies/ml reduction after only 12 weeks of treatment. The mean HBV DNA suppression after 1-year treatment of adefovir and of entecavir (1 mg daily) in lamivudine-resistant patients are 4.0 logs copies/ml and 5.1 logs copies/ml, respectively. 5,14 This suggests that greater viral suppression may be achieved by LB In the present study, there was an increase of median HBV DNA at 16 weeks (i.e., 4 weeks after switching from LB80380 to adefovir) in group 5 (Fig. 2). All 13 episodes of virologic rebound occurred after switching to adefovir. The highest dose of LB80380 (group 5) had earlier virologic rebound. This was presumably related to the greater suppression of HBV DNA with this dosage. However, it should be noted that the study was not empowered statistically to compare the efficacy between these two antiviral agents. The HBV DNA reduction achieved by LB80380 and tenofovir appears to be comparable. The mean HBV DNA reduction at week 12 was 4.16 logs copies/ml for LB80380 and 4.5 logs copies/ml for tenofovir. 15 However, head-to-head comparative studies must be performed for more definite conclusions. It has been shown in in vitro studies that, of nine mutants resistant to lamivudine, adefovir, entecavir, or telbivudine tested, LB80380 is as potent against six of these as the wild-type virus. 13 Two other mutants have a small decrease ( 7-fold) in sensitivity to LB Thus, LB80380 may have an important role in controlling single drug-resistant HBV. Though adefovir and tenofovir are both acyclic phosphonates, a preliminary study has shown that tenofovir is effective in suppressing the HBV DNA levels in adefovir-resistant HBV. 7 It is therefore worthwhile to further investigate the efficacy of LB80380 for HBV resistant to either nucleoside analogues or nucleotide analogues. This can provide more complementary coverage of drug-resistant HBV. We did not observe a dose-proportional effect on HBeAg seroconversion, loss of HBsAg, and ALT normalization. This is likely related to the statistical limitations because of the limited number of patients achieving these events within a short period of treatment. Concerning the ALT normalization, we cannot exclude the possibility of drug-induced ALT elevation even though there is no documented liver derangement associated with LB80380 in preclinical or phase I studies. LB80380 was safe for the study period of 12 weeks. All the adverse events were considered to be not related to the medication. The most frequently reported adverse events were cough and headache and occurred primarily in the
9 HEPATOLOGY, Vol. 51, No. 3, 2010 YUEN, HAN, ET AL. 775 Fig. 4. Creatinine clearance of all the study patients in the five groups at baseline, week 12, and week 36. lowest-dose group (group 1), suggesting no evidence for a dose-related trend. Comparing baseline CrCl with posttreatment CrCl, there is no clear finding to conclude that LB80380 treatment has a negative impact on renal function in terms of CrCl. Some patients CrCl decreased after initiation of LB80380 treatment (data not shown); however, the number of patients with decreased CrCl was not increased dose-dependently, and most of the changes were considered as normal fluctuation. The present study had two limitations. First, it did not recruit a group of patients with lamivudine-resistant disease continuing with lamivudine monotherapy to act as a control population. Second, the duration of LB80380 treatment was only 12 weeks. A longer study would allow better surveillance for possible viral mutations. The efficacious results from the present study of patients with lamivudine-resistant disease, a previous study on treatment-naïve patients, 12 and an in vitro study 8 suggest that LB80380 may be a good new antiviral agent in the armamentarium of the treatment of chronic hepatitis B. In conclusion, the results of the present study suggest that LB80380 at doses of up to 240 mg is safe, well tolerated, and effective at reducing viral load in adult patients with lamivudine-resistant chronic hepatitis B for a period of 12 weeks. LB80380 showed promising results causing profound viral suppression after only 12 weeks of therapy. Further clinical investigation focusing on long-term treatment should be performed to verify the effects and safety of this compound for the treatment of chronic hepatitis B viral infection in both treatment-naïve and lamivudineresistant patients. References 1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-68.
10 776 YUEN, HAN, ET AL. HEPATOLOGY, March Lai CL, Yuen MF. Chronic hepatitis B new goals, new treatment. N Engl J Med 2008;359: Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147: Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12: Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126: Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008;2:A88-A Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359: Trojan J, Stuermer M, Teuber G, Berger A, Faust D. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? Gut 2007;56: Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trépo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46: Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008;17: Kim GW, Roh KY, Kim J. Evaluation of mitochondrial toxicities of new phosphonate derivatives. Intersci Conf Antimicrob Agents Chemother 2002;42:F Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006; 11: Min CH, Kim CR, Steffy K, Averett D, Locarnini S, Shaw T. The active metabolite of LB80380/ANA380, a novel nucleotide analog, exhibits activity in vitro against multiple clinically relevant hepatitis B virus mutants. J Hepatol 2007;46(Suppl 1):S Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130: van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004;40:
Management of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationAntiviral Therapy 14:
Antiviral Therapy 14:679 685 Original article Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy Man-Fung Yuen 1 *,
More informationChronic Hepatitis B - Antiviral Resistance in Korea -
Chronic Hepatitis B - Antiviral Resistance in Korea - Young-Suk Lim University of Ulsan College of Medicine Asan Medical Center Seoul, Korea HBV Genome partially double-stranded DNA genome about 3200 nucleotides
More informationChronic hepatitis B - New goals, new treatment. New England Journal Of Medicine, 2008, v. 359 n. 23, p
Title Chronic hepatitis B - New goals, new treatment Author(s) Lai, CL; Yuen, MF Citation New England Journal Of Medicine, 2008, v. 359 n. 23, p. 2488-2491 Issued Date 2008 URL http://hdl.handle.net/10722/59270
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationA randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B
Antiviral Therapy 11:977 983 A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B Man-Fung Yuen 1 *, John Kim 2, Chung Ryeol Kim 2, Vincent
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationFinal Clinical Study Report. to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI463110
BMS-475 AI463 Name of Sponsor/Company: Bristol-Myers Squibb Individual Study Table Referring to the Dossier For National Authority Use Only) Name of Finished Product: Baraclude Name of Active Ingredient:
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationLong-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease
Antiviral Therapy 12:1295 133 Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Man-Fung Yuen, Wai-Kay
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationDisclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only
Disclaimer Presenter Release are for reactive use by Medical Information only internal learning/educational use only Any unsolicited request from HCP must be forwarded to Medical Information Housekeeping
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationApproximately 400 million people worldwide have. Hepatitis B Virus DNA Levels at Week 4 of Lamivudine Treatment Predict the 5-Year Ideal Response
Hepatitis B Virus DNA Levels at Week 4 of Lamivudine Treatment Predict the 5-Year Ideal Response Man-Fung Yuen, Daniel Yee-Tak Fong, Danny Ka-Ho Wong, John Chi-Hang Yuen, James Fung, and Ching-Lung Lai
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationTreatment of chronic hepatitis B: Evolution over two decades_
doi:10.1111/j.1440-1746.2010.06545.x REVIEW Treatment of chronic hepatitis B: Evolution over two decades_6545 138..143 Man-Fung Yuen and Ching-Lung Lai Department of Medicine, the University of Hong Kong,
More informationEntecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients
Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve Patients D.J. Tenney 1, K.A. Pokorowski 1, R.E. Rose 1, C.J. Baldick 1, B.J. Eggers 1, J. Fang 1, M.J. Wichroski 1,
More informationIdentification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir
Title Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir Author(s) Wong, DKH; Fung, JYY; Lai, CL; Yuen, RMF Citation Hong Kong Medical
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen Positive Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1047 1050 BRIEF COMMUNICATIONS High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen Positive
More informationAntiviral Therapy 2012; 17: (doi: /IMP1945)
Antiviral Therapy 2012; 17:387 394 (doi: 10.3851/IMP1945) Original article HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine
More informationC hronic hepatitis B (CHB) virus infection affects more
161 HEPATITIS Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications MF Yuen, HJ Yuan, D KH Wong, J CH Yuen, WM Wong, A OO Chan, B CY Wong, KC Lai, CL Lai... See end of article
More informationRecent achievements in the treatment of hepatitis B by nucleosides and nucleotides. K. Zhdanov
EASL endorsed conference White Nights of Hepatology 2012 Adverse events during antiviral therapy: how to predict, manage and monitor June 7-8 Saint-Petersburg Recent achievements in the treatment of hepatitis
More informationOriginal article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B
Antiviral Therapy 2011; 16:469 477 (doi: 10.3851/IMP1772) Original article Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B Young Eun Chon 1, Seung Up Kim
More informationJournal of Antimicrobial Chemotherapy Advance Access published April 25, 2013
Journal of Antimicrobial Chemotherapy Advance Access published April 25, 213 J Antimicrob Chemother doi:1.193/jac/dkt147 Virological response to entecavir reduces the risk of liver disease progression
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationChronic hepatitis B virus (HBV) infection is an important. New and Emerging Treatment of Chronic Hepatitis B
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:285 294 New and Emerging Treatment of Chronic Hepatitis B EMMET B. KEEFFE* and PATRICK MARCELLIN *Division of Gastroenterology and Hepatology, Stanford University
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationLandmarks for Prevention and Treatment
HBeAg-positive chronic hepatitis B Why do I treat my patient with a nucleos(t)ide analogue? Dr. Nancy Leung BSc(Lon) MSc(Lon) MBBS(Lon) MD(Lon), FRCP(Lon) FRCP(Edin) FHKCP FHKAM Consultant Physician, Alice
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationThe role of entecavir in the treatment of chronic hepatitis B
REVIEW The role of entecavir in the treatment of chronic hepatitis B Evangelini Dimou Vasilios Papadimitropoulos Stephanos J Hadziyannis Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens,
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationASSESSMENT REPORT FOR HEPSERA. International Nonproprietary Name: Adefovir Dipivoxil. Procedure No. EMEA/H/C/485/II/30
London, 4 January 8 Product Name: Hepsera Procedure Number: EMEA/H/C/485/II/3 ASSESSMENT REPORT FOR HEPSERA International Nonproprietary Name: Adefovir Dipivoxil Procedure No. EMEA/H/C/485/II/3 7 Westferry
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated Interferon alfa 2a, 180 mcg for subcutaneous injection (Pegasys ) No. (186/05) Roche New indication (chronic hepatitis B) 10 June 2005 The Scottish Medicines Consortium
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationJ.C. WANG, L.L. HE, Q. CHEN 1. Introduction. Abstract. BACKGROUND: Either combination. European Review for Medical and Pharmacological Sciences
European Review for Medical and Pharmacological Sciences Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation
More informationResponse-guided antiviral therapy in chronic hepatitis B: nucleot(s)ide analogues vs. pegylated interferon
Response-guided antiviral therapy in chronic hepatitis B: Sang Hoon Ahn, M.D., Ph.D. Department of Internal Medicine, Yonsei University College of Medicine, Institute of Gastroenterology, Liver Cirrhosis
More informationEntecavir for the treatment of chronic hepatitis B infection
DOI: 10.3310/hta13suppl3/05 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Entecavir for the treatment of chronic hepatitis B infection J Shepherd,* E Gospodarevskaya, G Frampton and K Cooper Southampton
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationTRANSPARENCY COMMITTEE OPINION. 8 July 2009
The legally binding text is the original French version TRAPARENCY COMMITTEE OPINION 8 July 2009 VIREAD 245 mg film-coated tablets Bottle 30 tablets (CIP: 358 500-1) Applicant: GILEAD SCIENCES Tenofovir
More informationReceived 26 September 2008/Returned for modification 9 December 2008/Accepted 31 January 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2009, p. 1779 1785 Vol. 53, No. 5 0066-4804/09/$08.00 0 doi:10.1128/aac.01290-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Pharmacokinetics
More informationVirologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
The Korean Journal of Hepatology 2011;17:261-267 http://dx.doi.org/10.3350/kjhep.2011.17.4.261 Original Article Virologic response is not durable after adefovir discontinuation in lamivudine-resistant
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationHow to use pegylated Interferon for Chronic Hepatitis B in 2015
How to use pegylated Interferon for Chronic Hepatitis B in 215 Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University, Thailand ASIAN-PACIFIC CLINICAL PRACTICE
More informationDepartment of Internal Medicine, Konkuk University School of Medicine, Konkuk University Hospital, Seoul, South Korea 2
Antiviral Therapy 9 1:95 993 (doi: 1.351/IMP117) Original article Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir
More informationSponsor Generic Drug Name Therapeutic Area of Trial Approved Indication Study Number Title Phase of Development Study Start/End Dates
Sponsor Novartis Farmacéutica, S.A Generic Drug Name Telbivudine Therapeutic Area of Trial Antiviral for systemic use Approved Indication Treatment of chronic hepatitis B (CHB) in adult patients with compensated
More informationHigh efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
The Korean Journal of Hepatology 2012;18:75-83 http://dx.doi.org/10.3350/kjhep.2012.18.1.75 pissn: 1738-222X eissn: 2093-8047 Original Article High efficacy of adefovir and entecavir combination therapy
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationChronic HBV Management in 2013
Chronic HBV Management in 2013 Mohammad Hossein Somi MD Professor of Gastroentrology and hepatology Liver and Gastrointestinal Disease Research Center Tabriz University of Medical Sciences 1 HBV in 2013
More informationLarge-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B
ORIGINAL ARTICLE Korean J Intern Med 2018;33:91-101 Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B Chang Wook Kim 1, Chang Seop
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationClinical Study High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B
Hepatitis Research and Treatment, Article ID 615621, 5 pages http://dx.doi.org/10.1155/2014/615621 Clinical Study High Dose of Lamivudine and Resistance in Patients with Chronic Hepatitis B Hamid Ullah
More informationClinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience
pissn 2287-2728 eissn 2287-285X Original Article https://doi.org/10.3350/cmh.2017.0005 Clinical and Molecular Hepatology 2017;23:323-330 Clinical characteristics of patients with chronic hepatitis B who
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationChronic infection with the hepatitis B virus (HBV)
Adding-on Versus Switching-to Adefovir Therapy in Lamivudine-Resistant HBeAg-Negative Chronic Hepatitis B Irene Rapti, 1 Evangelini Dimou, 1,2 Panayota Mitsoula, 2 and Stephanos J. Hadziyannis 1,2 We studied
More information< ) ETV
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen Positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir Nancy Leung, 1 Cheng-Yuan Peng,
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationSeroclearance of the hepatitis B surface antigen
A Large Case-Control Study on the Predictability of Hepatitis B Surface Antigen Levels Three Years Before Hepatitis B Surface Antigen Seroclearance Wai-Kay Seto, 1 Danny Ka-Ho Wong, 1 James Fung, 1 Ivan
More informationSYNOPSIS. Clinical Study Report AI Addendum #1. Open-label Dosing Phase
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: Entecavir SYNOPSIS Clinical
More informationThe presence of hepatitis B e antigen (HBeAg) is
Assessment of Current Criteria for Primary Nonresponse in Chronic Hepatitis B Patients Receiving Entecavir Therapy Young-Joo Yang, 1 Ju Hyun Shim, 2 Kang Mo Kim, 2 Young-Suk Lim, 2 and Han Chu Lee 2 A
More informationCurrent treatment guidelines consider nucleos(-
Entecavir Treatment for Chronic Hepatitis B: Adaptation Is Not Needed for the Majority of Naïve Patients with a Partial Virological Response Roeland Zoutendijk, 1 Jurriën G. P. Reijnders, 1 Ashley Brown,
More informationDual Therapy for Chronic Hepatitis B Virus
Dual Therapy for Chronic Hepatitis B Virus Hussien Elsiesy, MD, and Douglas Dieterich, MD Corresponding author Douglas Dieterich, MD Division of Liver Diseases, Mount Sinai School of Medicine, One Gustave
More informationEffects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
Gut and Liver, Vol. 11, No. 6, November 2017, pp. 828-834 ORiginal Article Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationClinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B
pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 217;23:154-159 Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve
More informationLong-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients
ORIGINAL ARTICLE Korean J Intern Med 2015;30:32-41 Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients Hyo Jin Kim,
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationJMSCR Vol 05 Issue 06 Page June 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i6.02 An Open Label Prospective Study to Evaluate
More informationA tale of two patients
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sanjay Bhagani Royal Free Hospital, London Thursday 29 September 2011, Royal College of Physicians, London A tale of two patients Sanjay Bhagani
More informationIs there a need for combination treatment? Yes!
18.0.2012 C Hep Meeting Berlin Is there a need for combination treatment? Yes! Florian van Bömmel University Hospital Leipzig Hepatology Section Germany Most patients respond to monotherapy with entecavir
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationLow Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients
GASTROENTEROLOGY 2007;133:1445 1451 Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B Patients PIETRO LAMPERTICO,* MAURO VIGANÒ,* ELENA MANENTI,*
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationcasebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach
casebasedhepatitis bmanagement Management of Hepatitis B: A Case-based Approach In order to receive credit for this activity, please complete the post-test by recording the best answer to each question
More informationEmerging Drug List ADEFOVIR DIPIVOXIL FOR HEPATITIS B VIRUS INFECTION NO. 48 SEPTEMBER Generic (Trade Name): Adefovir dipivoxil (Hepsera TM )
Generic (Trade Name): Manufacturer: Adefovir dipivoxil (Hepsera TM ) Gilead Sciences, Inc. NO. 48 SEPTEMBER 2003 Indication: Current Regulatory Status: For the treatment of adults showing evidence of active
More informationPartial virological response to entecavir in treatment-naïve patients with chronic hepatitis B
Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B Young Eun Chon Department of Medicine The Graduate School, Yonsei University Partial virological response
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationReceived 30 May 2004/Returned for modification 6 August 2004/Accepted 12 August 2004
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2004, p. 5036 5040 Vol. 42, No. 11 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.11.5036 5040.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationMF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9
SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab
More informationHepatitis B virus infection (HBV) is global epidemic. Current Treatment Strategies for the Management of Chronic Hepatitis B CHRONIC HEPATITIS B
CHRONIC HEPATITIS B Current Treatment Strategies for the Management of Chronic Hepatitis B Case Study and Commentary, Robert J. Wong, MD, and Walid S. Ayoub, MD ABSTRACT Objective: To review current treatment
More informationOriginal article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV
Antiviral Therapy 2016; 21:605 609 (doi: 10.3851/IMP3066) Original article Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV Edward J Gane 1,2 *, Robert H Hyland 3, Di An 3, Evguenia
More informationDynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative Chronic Hepatitis B
ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY (2007) 25: 183-188 CASE REPORT Dynamics of HBV DNA Levels, HBV Mutations and Biochemical Parameters during Antiviral Therapy in a Patient with HBeAg-Negative
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationPegasys Hepatitis B. Pegasys (peginterferon alfa-2a) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.02 Subject: Pegasys Hepatitis B Page: 1 of 5 Last Review Date: September 18, 2015 Pegasys Hepatitis
More information